17:56 , May 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Rett syndrome Patient sample and mouse studies suggest inhibiting GSK3B could help treat Rett syndrome. In postmortem cerebellum tissue samples from Rett syndrome patients, levels of GSK3B were higher than in samples from unaffected...
20:58 , Mar 1, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: February 2018

New Therapeutic Targets and Biomarkers: February 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during February 2018. Therapeutic targets are defined as any protein, gene or other...
16:29 , Feb 7, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs; plasma markers Loss-of-function mutations in SLC7A8 could help predict the risk of age-related hearing loss. Whole-genome sequencing in blood samples from 66 age-related hearing loss patients and 81 healthy, elderly volunteers identified four...
07:00 , Oct 19, 2015 |  BioCentury  |  Finance

From Actos to act two

The improved properties of Minoryx Therapeutics S.L .'s backup PPAR gamma agonist versus lead molecule pioglitazone were enough to convince Ysios Capital to lead the rare disease company's €19.4 million ($22.1 million) series A round....
07:00 , Sep 7, 2015 |  BC Week In Review  |  Company News

Bellvitge, Oxford Immunotec Global deal

Bellvitge granted Oxford exclusive rights to use B cell-measuring technology to develop and commercialize one or more diagnostics to measure the risk of transplant rejection. Bellvitge declined to provide further details, and Oxford could not...
07:00 , Apr 21, 2014 |  BioCentury  |  Emerging Company Profile

Minoryx: Mediating rare metabolism

Minoryx Therapeutics S.L. has two complementary strategies for developing therapies to treat inherited metabolic diseases involving enzyme deficiencies: identifying small molecule chaperones that can restore mutant enzyme function, and repurposing existing drugs to treat the...
08:00 , Feb 20, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Lung cancer SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily a member 4 (SMARCA4; BRG1) Cell culture studies suggest inhibiting BRG1 could help treat MYC associated...
07:00 , Mar 17, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Colorectal cancer TAR (HIV-1) RNA binding protein 2 (TARBP2) Cell culture and mouse studies suggest that small molecule agonists of TARBP2...
08:00 , Nov 15, 2010 |  BioCentury  |  Emerging Company Profile

VCN: Anti-tumor Ad-vantages

Pancreatic cancer is highly resistant to drugs because about 80% of the tumor is stroma - normal fibrous and connective tissues that support cancer cell growth and invasion - that compounds cannot penetrate efficiently. To...